MIR

Mirion Technologies, Inc. (MIR) - 2025 Annual Report Summary

Business Context and Reporting Period

This summary covers the Form 10-K for Mirion Technologies, Inc. for the fiscal year ended December 31, 2025. Mirion is a global provider of radiation detection, measurement, analysis, and monitoring products and services, operating in two primary segments: Nuclear & Safety (serving nuclear power, defense, and research) and Medical (serving cancer care and dosimetry). The company is headquartered in Atlanta, Georgia, with operations in 12 countries.

Key Financial Metrics (Fiscal Year 2025)

Material Changes vs. Prior Period

• Profitability Turnaround: The company returned to net profitability ($29.8M) from a net loss of $36.6M in 2024. This was driven by revenue growth, reduced interest expense, a $17.4M foreign currency gain, and lower amortization of intangible assets.
• Strategic Acquisitions: Mirion completed two major acquisitions in 2025:
  • Certrec Corporation (July 2025): $82.9M purchase price, enhancing regulatory compliance and digital solutions for the nuclear market.
  • Paragon Energy Solutions (December 2025): $588.4M purchase price, significantly expanding capabilities in U.S. nuclear power and Small Modular Reactors (SMRs).
• Capital Structure Optimization:
  • Issued $400M of 0.25% Convertible Senior Notes due 2030 and $375M of 0.00% Convertible Senior Notes due 2031.
  • Refinanced the Term Loan, repaying $244.6M of principal and extending the maturity to 2032.
  • Completed a public offering of Class A common stock raising approximately $425M gross proceeds.
• Segment Performance:
  • Nuclear & Safety: Revenue grew 9.5% to $614.6M; Operating Income grew 28.1% to $101.1M.
  • Medical: Revenue grew 3.7% to $310.8M; Operating Income more than doubled to $46.9M.

Guidance, Outlook, and Risks

Outlook & Strategy: Management expects continued growth driven by the nuclear energy renaissance (including SMRs and data center power demands), aging nuclear infrastructure requiring upgrades, and expanding medical oncology markets. The company aims to leverage its installed base for recurring revenue and pursue further strategic M&A.

Key Risks & Contingencies:

• Geopolitical & Trade: Exposure to sanctions and trade restrictions related to Russia and China. The company has approximately $103.2M in remaining performance obligations for Russian-related projects and $15.8M in receivables/contract assets.
• Fixed-Price Contracts: Risks associated with cost overruns on long-term, fixed-price nuclear construction contracts.
• Supply Chain: Dependence on third-party suppliers for specialized components and raw materials.
• Regulatory: Strict compliance requirements in nuclear and medical device sectors (FDA, NRC, etc.).

Investor Verification Checklist

• Acquisition Integration: Verify the integration progress and synergy realization of the Certrec and Paragon acquisitions, particularly given the late-year closing of Paragon.
• Debt Covenants: Confirm compliance with the "First Lien Net Leverage Ratio" covenant (max 7.00:1.00) under the Credit Agreement, especially given the new convertible debt structure.
• Russia Exposure: Assess the impact of ongoing sanctions on the $103.2M backlog and $15.8M receivables related to Russian customers.
• Convertible Notes Dilution: Review the conversion terms of the $775M in new convertible notes (2030 and 2031) and the associated capped call transactions to understand potential future dilution.
• Backlog Visibility: Validate the $1.104B remaining performance obligations, noting that 49% is expected to be recognized in 2026.